Substitu	e for form 1449A/PTO				COMPLETE IF KNOWN
INE	e for form 1449A/PTO ORMATION	DIS	CLOSURE	Application Number	10/556,805
ONFE	TEMENT BY	, A TO	DI ICANT	Filing Date	November 14, 2005
AUG 27	2007	AP	PLICANI	First Named Inventor	Tesfaye Biftu, et al
AUD -			,	Group Art Unit	1624
CAT & TRACE	ise aksinany sheets	as n	iecessary)	Examiner Name	Coleman
Sheet	1	of	4	Attorney Docket Number	21404P

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	US 4,386,090		Moinet, et al.	05/31/1983
	2	US 5,939,560		Jenkins, et al.	08/17/1999
	2	US 6,011,155		Vilhouse	01/04/2000
	-	U9-6;166;063		₩illiauer	12/26/2000
	-	US 6,303,661 B1		Demath, et al.	10/16/2001
	-	US 6,432,969 B1		Villimoer	08/13/2002
	2	US 6,699,871 B2			03/02/2004
	-	Op 6,679,671 DE		Edmondson, et al.	05/02/2001
			_		
	-		_		
			+		
		-	-		

			FOREIGN P	ATENT	DOCUMENT:	S			П
Examiner Initials*	Cite No.	Office	Foreign Patent Document  Number	Kind		atentec or Applican	ıt	Date of Publication of Cited Document	٦
initials	NO.			Code (if known)	or Ci	tea Document		MM-DD-YYYY	_
	1	PCT	WO 97/40832		Hors Horoll Institut Pa	Hatarstoft Forseliung	-0.4·	11/06/1997	_
	2	PCT	WO 98/19998		Novartis AG			05/14/1998	7
	9	PCT	WO 00/34241		Novartis AG			06/15/2000	7
	4	PCT	WO 01/34594 A1	_	Guilford Pharm	accuticals; Inc.		05/17/2001	_
	5	PCT	WO 01/42262 A2	_	Akzo Nobel N.	<b>/</b>		06/14/2001	4
	6	DCT	WO 01/06205 A2		Nevertie AG			12/20/2001	4
	7	PCT	WO 02/02560 A2		Neve Nordisk /	JC		01/10/2002	4
<u> </u>	8	PCT	WO 02/076450 A1	_	Merck & Co., In	ıc:		10/03/2002	7
	9-	PCT	WO-03/000100-A2		Merck & Co., In	nc.		01/03/2003	4
	18	PCT	WO 83/880181 A2	_	Merck & Co., I.			01/03/2003	_
Examin Signatu			/Brenda Coleman/			Date Considered	0	9/14/2008	う

\*Examine: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TIO: Commissioner for Patients, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form \* IDS Form\* (IDS Folder), Merck & Co. Inc., 80-282007).

$\overline{}$	Substitute for form 1449A/PTO			COMPLETE IF KNOWN			
	INFORMATION D	oiso	CLOSURE	Application Number	10/556,805		
	STATEMENT BY	ı DI	DE ECANIE	Filing Date	November 14, 2005		
	SIAIEMENI BY	API	PLICANI	First Named Inventor	Tesfaye Biftu, et al.		
				Group Art Unit	1624		
	(use as many sheets	as ne	ecessary)	Examiner Name	Coleman		
Shee	2	of	4	Attorney Docket Number	21404P		

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
			+		
	_				
			+		
			-		
			1		
	-			,	
			1		
			+		
			_		
			+		
	ļ				

			FOREIG	SN PATEN	T DOCUMENT	S	
Examiner Initials*	Cite No.	Office	Foreign Patent Document Number ,	Kind Code	of C	atentee or Application	Date of Publication of Cited Document MM-DD-YYYY
	11	rer wo	03/082817 A2		Merck & Co., In	ic.	10/09/2003
	12	rer wo	2004/007468 A1		Merck & Co., h	TC.	01/22/2004
	13	PCT WO	2004/032836 A.2		Morek & Co., I	10:	04/22/2004
	14	PCT WO	2004/043940 A1		Merek & Co., I.	rc:	05/27/2004
	15	PCT WO	2004/050022 A.2		Morels & Co., Is	16:	96/17/2004
	16	PCT WO	2004/058266 A1		Merek & Co., Is	10.	07/15/2004
	17	PCT WO	2004/064778 A.2		Morels & Co., Is	**	08/05/2004
	18	PCT WO	2004/069162 1\2		Merck & Co., h	ıc.	06/19/2004
ļ	19	PCT WO	2004/110436 A1		Merck & Co., L	10:	12/23/2004
	20-	PCT WO	2004/112701 A2		Morek & Co., I	10:	12/29/2004
Examin Signatu	er		nda Coleman/		1	Date Considered	09/14/2008

\*Examiner. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication p

Su	bstitute for form 1449A/PTO			COMPLETE IF KNOWN				
I	NFORMATION I	DIS	CLOSURE	Application Number	10/556,805`	-		
	TATEMENT DAY	4 D	DI ICANT	Filing Date	November 14, 2005			
8	TATEMENT BY	AP	PLICANI	First Named Inventor	Tesfaye Biftu, et al.			
				Group Art Unit	1624			
	(use as many sheets	as n	ecessary)	Examiner Name	Coleman .			
Sheet	3	of	4	Attorney Docket Number	21404P			

			U.S. PAT	ENT DOCUMENTS	
Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of
Initials*	No.	Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY
				· · · · · · · · · · · · · · · · · · ·	

			FOREIG	IN PATENT	DOCUMENTS			
Examiner Initials*	Cite No.	Office Number Co		Kind Code (if known)	Name of Patentee or Applie of Cited Document	cant	Date of Publication of Cited Document MM-DD-YYYY	
	21-	PCT	WO 2005/011581 A2		Merck & Co., Inc.		02/10/2005	
	22	PCT	WO 2005/044195 1.2		Merck & Co., Inc.		05/19/2005	
	22	PCT	WO 2005/056003 A1		Graffinity Pharmacouticals A	<u></u>	06/23/2005	
	24	PCT	WO 2005/056013 A1		Graffinity Pharmaceuticals A	6	06/23/2005	
	25	PCT	WO 2005/108382 A1		Merck & Co., Inc.		11/17/2005	
	26	PCT	WO 2005/116029 A1		Merck & Co., Inc.		12/08/2005	
	27	PCT	WO 2005/123685 A1		Astrazeneca AB		12/29/2005	
Examin Signatu			/Brenda Coleman/		Date Considered	09	/14/2008	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Si	bstitute for form 1449B/PTO				COMPLETE IF KNOWN
	NFORMATION	DIS	CLOSURE	Application Number	10/556,805
	STATEMENT BY APPLICANT		Filing Date	November 14, 2005	
3	IAIEMENI DI	AP	PLICANI	First Named Inventor	Tesfaye Biftu, et al
				Group Art Unit	1624
	(use as many sheets as necessary)		Examiner Name	Coleman	
Sheet	4	of	4	Attomey Docket Number	21404P

			NON PATENT LITERATURE DOCUMENTS
	xaminer nitials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
T		1	Augustyns, K. et al., "Dipeptidyl peptiduse IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes" Expert Opin. Ther. Patents, Vol. 13, No. 4, pp 499-510, 2003
			Augustyns, K. et al., "Inhibitors of proline specific dipoptidyl poptidases. DPP IV inhibitors as a novel
		2	approach for the treatment of Type 2 diabetes" Expert Opin. Ther. Patents, Vol. 15, No. 10, pp 1387-1407, 2005.
		<u> </u>	Deason, C. F., Perspectives in Diabetes Therapentic Strategies Based on Sheegen Like Poptide !
L		3	Diabetes, Vol. 53, pp 2181-2189, 2004
		<u></u>	Deacon, C. F. et al., "Inhibitors of dipeptidy! peptidase IV: a movel approach for the prevention and treatment
L		4	of Type 2 diabetes?" Expert Opin. Investig. Drugs, Vol. 13, No. 9, pp 1091-1102, 2004
L	/B.C./	5	Drucker, D. J., "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes" Expert Opin. Investig. Drugs, Vol. 12, No. 1, pp 87-100, 2003
			Hills I I III and CT O I I I I I I I I I I I I I I I I I I
		6	Holss, J. J., "Treatment of Type 2 diabetes mellitas with agonists of the GLP-1 receptor or BPP-IV inhibitors" Expert Opin. Emerg. Drugs, Vol. 9, No. 1, pp 155-166, 2004
┸			Knadson, L. D., "Glacagon-like Peptide-1. The Dasis of a New Class of Treatment for Type 2 Diabetes" J.
I		7	Med. Chem, Vol. 47, pp 4128-4134, 2004
	***************************************		November AG: WO0024241 "Nevel M substituted 2 symmepy relidines as potent inhibitors of dipeptidy!
L		8	peptidase IV in the treatment of non-insulin-dependent diabetes mellitus", Exp. Opin. Ther. Patents, Vol. 10, No. 12, pp 1937-1942, 2000
			Valid, T. P. et al., "Gut poptides in the treatment of diabetes mellitus", Expert Opin: Investig. Drugs, Vol. 13,
		9	No. 3, pp 177-188, 2004
		l	Holst, J. J. et al., "Glacagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2
		10	diabetes mellitus" Current Opinion in Pharmacology, Vol. 4, pp 589-596, 2004
			Demath, H. U. et al., "Type 2 diabetes Therapy with dipoptidyl poptidase IV inhibitors" Biochimica et
L		11	Biophysica Acta, Vol. 1751, pp 33-44, 2005
			Websen A. F. IIDisancidal Devides BVIII in C. of T CD: 1 . III AC 1 C.
T		12	Weber, A. E., "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes" J. Med. Chem, Vol. 47, pp 4135-4141, 2004
$\vdash$			
1			
- 1			
t			

$\overline{}$			
Examiner Signature	/Brenda Coleman/	Date Considered	9/14/2008